The Manufacturers Life Insurance Company Has $23.55 Million Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

The Manufacturers Life Insurance Company increased its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 159.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 193,652 shares of the biotechnology company's stock after buying an additional 118,874 shares during the period. The Manufacturers Life Insurance Company owned 0.20% of Sarepta Therapeutics worth $23,546,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of SRPT. Manchester Capital Management LLC boosted its position in shares of Sarepta Therapeutics by 86.6% in the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company's stock worth $29,000 after purchasing an additional 110 shares during the last quarter. MassMutual Private Wealth & Trust FSB boosted its holdings in Sarepta Therapeutics by 169.6% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company's stock worth $30,000 after buying an additional 156 shares during the last quarter. Newbridge Financial Services Group Inc. bought a new position in Sarepta Therapeutics during the fourth quarter worth about $36,000. Steward Partners Investment Advisory LLC increased its stake in shares of Sarepta Therapeutics by 164.4% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company's stock valued at $38,000 after acquiring an additional 194 shares during the last quarter. Finally, Smartleaf Asset Management LLC increased its stake in shares of Sarepta Therapeutics by 95.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 442 shares of the biotechnology company's stock valued at $54,000 after acquiring an additional 216 shares during the last quarter. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Sarepta Therapeutics Stock Performance

NASDAQ SRPT traded down $9.77 on Wednesday, hitting $36.99. 15,991,319 shares of the stock were exchanged, compared to its average volume of 1,550,972. The company has a market capitalization of $3.63 billion, a PE ratio of 29.73 and a beta of 0.85. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. The business's fifty day moving average is $70.87 and its 200 day moving average is $102.57. Sarepta Therapeutics, Inc. has a 52 week low of $36.75 and a 52 week high of $173.25.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last issued its earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.20 by ($5.62). Sarepta Therapeutics had a net margin of 7.43% and a return on equity of 11.00%. The firm had revenue of $744.86 million during the quarter, compared to the consensus estimate of $685.75 million. During the same period in the previous year, the company posted $0.73 earnings per share. The firm's revenue for the quarter was up 80.2% compared to the same quarter last year. Research analysts anticipate that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current fiscal year.

Insider Buying and Selling at Sarepta Therapeutics

In related news, Director Claude Nicaise sold 2,491 shares of the business's stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total transaction of $248,203.24. Following the transaction, the director now directly owns 27,812 shares of the company's stock, valued at approximately $2,771,187.68. The trade was a 8.22 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 7.70% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on SRPT shares. Deutsche Bank Aktiengesellschaft lowered their target price on shares of Sarepta Therapeutics from $124.00 to $99.00 and set a "hold" rating for the company in a research note on Wednesday, March 19th. The Goldman Sachs Group lowered their price objective on shares of Sarepta Therapeutics from $178.00 to $100.00 and set a "buy" rating for the company in a research report on Wednesday. Oppenheimer reduced their target price on Sarepta Therapeutics from $184.00 to $123.00 and set an "outperform" rating on the stock in a report on Wednesday. Morgan Stanley lowered their price target on Sarepta Therapeutics from $182.00 to $113.00 and set an "overweight" rating for the company in a report on Wednesday. Finally, Cantor Fitzgerald cut their price objective on Sarepta Therapeutics from $163.00 to $81.00 and set an "overweight" rating on the stock in a report on Wednesday. Six analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $137.09.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.